Parsaclisib is a Small Molecule owned by Incyte, and is involved in 30 clinical trials, of which 11 were completed, 16 are ongoing, and 3 are planned.

Parsaclisib is an inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. The drug candidate inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.

The revenue for Parsaclisib is expected to reach a total of $539m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Parsaclisib NPV Report.

Parsaclisib is originated and owned by Incyte. Innovent Biologics is the other company associated in development or marketing of Parsaclisib.

Parsaclisib Overview

Parsaclisib is under development for the treatment of indolent/aggressive B-cell non-Hodgkin's lymphoma, mantle cell lymphoma, hairy cell leukemia, Waldenstrom macroglobulinemia, Hodgkin's lymphoma, follicular lymphoma, relapsed/refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma, salivary gland cancer, marginal zone lymphoma including extranodal, nodal, and splenic subtypes, newly diagnosed triple negative breast cancer, and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and autoimmune hemolytic anemia. It is a small molecule administered orally in the form of tablet. It acts by targeting phosphoinositide 3-kinase delta (PI3Kdelta).

The therapeutic candidate was also under development for HER2-positive breast cancer, endometrial cancer, gastric cancer, small cell lung cancer, triple negative breast cancer, ureter cancer, bladder, urethral cancer, head and neck cancer squamous cell carcinoma, melanoma, colorectal cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, triple-negative breast cancer, transitional cell carcinoma, pemphigus vulgaris and Sjogren's syndrome. It was under development for the treatment of relapsed and refractory diffuse large B-cell lymphoma, peripheral t-cell lymphoma, including peripheral t-cell lymphoma, unspecified type, anaplastic large cell lymphoma (ALK negative or positive), angioimmunoblastic T-cell lymphoma, enteropathy related T-cell lymphoma, hepatosplenic T-cell lymphoma, γ/δ T-cell lymphoma, NK/T-cell lymphoma.

Innovent Biologics Overview

Innovent Biologics is a biopharmaceutical company that focuses on the research, development and manufacturing of monoclonal antibodies. It provides products for various diseases such as metabolic, cancer, autoimmune diseases and other therapeutic areas. The company oncology products include sintilimab injection, bevacizumab injection, rituximab injection, pemigatinib, olverembatinib, ramucirumab, and others. Its autoimmune drugs are adalimumab injection, IBI-353, IBI-112, IBI-314, among others. The company’s metabolic and ophthalmology products include IBI-306, IBI-362, IBI-302, IBI-324, IBI-311

The company reported revenues of (Renminbi) CNY4,269.7 million for the fiscal year ended December 2021 (FY2021), an increase of 11.1% over FY2020. The operating loss of the company was CNY2,988.6 million in FY2021, compared to an operating loss of CNY790.4 million in FY2020. The net loss of the company was CNY3,138.1 million in FY2021, compared to a net loss of CNY998.4 million in FY2020.

Quick View – Parsaclisib

Report Segments
  • Innovator
Drug Name
  • Parsaclisib
Administration Pathway
  • Oral
Therapeutic Areas
  • Hematological Disorders
  • Immunology
  • Oncology
Key Companies
Highest Development Stage
  • Filing rejected/Withdrawn

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.